Mixing does not improve mechanical properties of all bone cements

Hansen, Dick; Jensen, Jørgen Steen

doi:10.3109/17453679209154841

Cited by 45 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strength and elastic modulus values obtained in this study for standard cement, either with or without antibiotics, are in agreement with those reported in the literature 13,54,55 . The microcomposite cement formulation had less bending strength than, yet similar elastic modulus to, both plain and antibiotic‐containing standard cement, a resultant cost of the increased porosity that allows the substantially enhanced drug‐release kinetics observed here.…”

Section: Discussionsupporting

confidence: 90%

Novel microcomposite implant for the controlled delivery of antibiotics in the treatment of osteomyelitis following total joint replacement

İnceoğlu

Botimer

Maskiewicz

2020

Journal Orthopaedic Research

View full text Add to dashboard Cite

The objective of this study was to develop a novel microcomposite implant to be used in the treatment of osteomyelitis following total joint arthroplasty, with the dual purpose of releasing high local concentrations of antibiotic to eradicate the infection while providing adequate mechanical strength to maintain the dynamic or static spacer. Vancomycin‐loaded microcomposite implants were fabricated by incorporating drug‐loaded microparticles comprised of mesoporous silica into commonly employed polymethylmethacrylate (PMMA) bone cement, to yield a final drug loading of 10% w/w. In vitro release kinetics at 37°C were monitored by reverse‐phase high‐performance liquid chromatography, and compared to the release kinetics of current therapy implants consisting of drug alone incorporated at 10% w/w directly into PMMA bone cement. Results demonstrated a sevenfold improvement in the elution profile of microcomposite systems over current therapy implants. In vivo delivery of vancomycin to bone from microcomposite implants (70% of payload) was significantly higher than that from current therapy implants (approx. 22% of payload) and maintained significantly higher bone concentrations for up to 2 weeks duration. The elastic modulus showed no statistical difference between microcomposite implants and current standard therapy implants before drug elution, and maintenance of acceptable strength of microcomposite implants postdrug elution. These results demonstrate that we have developed a novel microcomposite spacer that will release continuously high antibiotic concentrations over a prolonged period of time, offering the possibility to eliminate infection and avoid the emergence of new resistant bacterial strains, while maintaining the requisite mechanical properties for proper space maintenance and joint fixation.

show abstract

Section: Discussionsupporting

confidence: 90%

Novel microcomposite implant for the controlled delivery of antibiotics in the treatment of osteomyelitis following total joint replacement

İnceoğlu

Botimer

Maskiewicz

2020

Journal Orthopaedic Research

View full text Add to dashboard Cite

show abstract

“…The mechanical strength of bone cement yield the similar trend in wet conditions bone cement immersed in artificially created BSF. Even though there was slight decrease in mechanical properties of modified bone cements from that of control unmodified PMMA bone cements which were devoid of dendrimers, but still these values are in the approved range given in the literature for bone cement formulations . CS of modified cement was compared with commercially available Simplex P ® (Stryker) by adding 5% of TPGDA G1.0 QOI in their liquid component, which is cured during the mixing state of making dough with solid PMMA powder.…”

Section: Resultsmentioning

confidence: 99%

“…Even though there was slight decrease in mechanical properties of modified bone cements from that of control unmodified PMMA bone cements which were devoid of dendrimers, but still these values are in the approved range given in the literature for bone cement formulations. [29][30][31] CS of modified cement was compared with commercially available Simplex P V R (Stryker) by adding 5% of TPGDA G1.0 QOI in their liquid component, which is cured during the mixing state of making dough with solid PMMA powder. The results demonstrated reduction in the CS on introduction of dendritic structures with the solid matrix of cement.…”

Section: Mechanical Testingmentioning

confidence: 99%

Formulation and characterization of antimicrobial quaternary ammonium dendrimer in poly(methyl methcarylate) bone cement

Abid

Jain

Jackeray

et al. 2015

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

The use of novel antimicrobial molecules in bone cement can improve efficiency of recuperation after arthroplasty or joint replacement surgeries, avoiding the risks associated with antibiotic resistant antimicrobial agents. Nanomaterials particularly dendrimers are particularly useful for making broad spectrum killing agents owing to their large surface areas and functionalities. Therefore, we have synthesized generation 1 quaternary ammonium dendrimer of tripropylene glycol diacrylate (TPGDA) using octyl iodide (OI) [TPGDA G1.0 (=) quaternary octyl iodide (QOI)] and capitalized on their capabilities of contact killing based mechanism. We formulated different TPGDA G1.0 (=) QOI antimicrobial agent loaded liquid component composed of methyl methacrylate monomer and N,N-dimethyl-p-toluidine coinitiator. Different polymethyl methacrylate (PMMA) based experimental bone cement formulations were made and dendrimer concentration was optimized. Mechanical strength and compressive modulus of modified bone cement decreased on increasing concentrations and 10% was optimized for further analysis. The mechanical strength of bone cement yield the similar trend in wet conditions bone cement immersed in artificially created stimulated body fluids. Ten percent TPGDA G1.0 (=) QOI in bone cement was sufficient to kill gram positive and negative bacteria and its property is retained even after a period of 30 days. Thus novel dendritic structures show promise for clinical antimicrobial activity while retaining mechanical properties of bone cements. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 521-530, 2017.

show abstract

“…There was no significant difference in each of the properties determined (compressive strength, four‐point bend strength, deflection in four‐point bending, and the four‐point bending modulus) of Palacos R and Palacos G, regardless of whether the cement powder and liquid monomer were mixed manually, in a centrifuge, or in a vacuum system 92…”

Section: In Vitro Mechanical Propertiesmentioning

confidence: 88%

“…91 There was no significant difference in each of the properties determined (compressive strength, four-point bend strength, deflection in four-point bending, and the four-point bending modulus) of Palacos R and Palacos G, regardless of whether the cement powder and liquid monomer were mixed manually, in a centrifuge, or in a vacuum system. 92 The addition of either tobramycin or vancomycin to Zimmer Regular produced no significant effect on the fourpoint bending strength of the cement, when the specimens were tested in water at 378C, regardless of whether the cement powder and liquid monomer were mixed manually or in a vacuum chamber; however, the flexural modulus of the vacuum-mixed plain cement was significantly higher than that for all the other groups. 93 Although the addition of vancomycin to vacuum-mixed Simplex P did not significantly affect the compressive strength of the cement, its fatigue life was significantly reduced.…”

Section: In Vitro Mechanical Properties Influence Of Antibioticmentioning

confidence: 88%

Properties of antibiotic‐loaded acrylic bone cements for use in cemented arthroplasties: A state‐of‐the‐art review

Lewis

2008

J Biomed Mater Res

View full text Add to dashboard Cite

Infection of periprosthetic sites of total joint replacements has been widely reported. Although, by most accounts, the incidence of such events is low, the problem can prove to be expensive to remedy. In the case of cemented arthroplasties, a common management modality is the use of antibiotic-loaded acrylic bone cement (ALABC) as a prophylaxis or a therapeutic agent. Although there is a large literature on properties of ALABCs (on the order of 100 journal articles), a comprehensive review is lacking. The present contribution, whose objective is to fill this gap, is organized in four parts. Details of the background to and motivation for the work are given in the first part, explicative summaries of literature studies on the influence of various factors on an array of in vitro and in vivo properties of ALABCs are covered in the second part, issues and areas for future studies are presented in the third part, and the fourth part contains a summary of the most salient points made in the review.

show abstract

Mixing does not improve mechanical properties of all bone cements

Cited by 45 publications

References 11 publications

Novel microcomposite implant for the controlled delivery of antibiotics in the treatment of osteomyelitis following total joint replacement

Novel microcomposite implant for the controlled delivery of antibiotics in the treatment of osteomyelitis following total joint replacement

Formulation and characterization of antimicrobial quaternary ammonium dendrimer in poly(methyl methcarylate) bone cement

Properties of antibiotic‐loaded acrylic bone cements for use in cemented arthroplasties: A state‐of‐the‐art review

Contact Info

Product

Resources

About